Active Ingredient: This medication contains the main active ingredient Abiraterone Acetate. This component is a sterol ester obtained by formal condensation of the 3-hydroxy group of abiraterone with the carboxy group of acetic acid. It is used for the treatment of metastatic castrate-resistant prostate cancer. It plays as a role of a prodrug, an antineoplastic agent, and steroid alpha-monooxygenase inhibitor. The drug is a member of pyridines, which is derived from an abiraterone.
It shows antiandrogen activity, which inhibits the enzymatic activity of steroid alpha-monooxygenase, a member of the cytochrome that catalyzes the alpha-hydroxylation of steroid intermediates. It is involved in testosterone synthesis.
Indications: The medication is used in combination with the steroid prednisone for the treatment of a certain type of late-stage prostate cancer in men. Especially in men who have already been treated with chemotherapy. The mentioned medicine is approved for the treatment of Metastatic castration-resistant prostate cancer (CRPC)and Metastatic high-risk castration-sensitive prostate cancer (CSPC).
Action Mechanism: This conventional tablet Zytiga targets a protein called CYP17A1, which plays a key role in the production of testosterone. It works by reducing the production of testosterone that stimulates cancer cells to keep growing.
Dosages: The given medicine Zytiga is approved for the treatment of prostate cancer in men. It is available in dosages as mentioned below:
- 250 mg: The pill is usually taken once per day with or without food. Follow the doctor’s dosing instructions very carefully
Note: This medication should not be handled by the pregnant woman. It is not approved for use by anyone younger than 18 years old.